

This Patient Group Direction (PGD) must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction

for the supply of

**Nystatin Oral Suspension 100,000 units in
1ml**

by registered pharmacists for the

**Treatment of Oral Candidiasis Thrush in Infants (from 1 to 23
months of age)**

under the Liverpool Clinical Commissioning Group Pharmacy First
Service

Version number: 1.0




Change history

Version number	Change details	Date
1.0	Original document developed with the Liverpool Medicines Optimisation Group (MOC)	December 2021
	Reviewed by LMC and approved by Clinical Effectiveness Committee	December 2021

PGD development

Name	Job title and organisation
Lead author	Peter Johnstone Head of Medicines Optimisation Liverpool CCG
Lead doctor	Dr Fiona Ogden-Forde Clinical lead for Prescribing Liverpool CCG
Lead pharmacist	Peter Johnstone Head of Medicines Optimisation Liverpool CCG
Representative of other professional group using PGD	Matt Harvey Pharmacist Chief Officer of Community Pharmacy Liverpool
Other members of the PGD working group: Members of Liverpool Medicines Optimisation Committee (date)	

PGD authorisation

Name	Job title and organisation	Signature	Date
Senior doctor	Dr Fiona Ogden-Forde Clinical lead for Prescribing Liverpool CCG		December 2021
Senior pharmacist	Peter Johnstone Head of Medicines Optimisation Liverpool CCG		December 2021
Person signing of behalf of CCG	Jane Lunt Head of Quality / Chief Nurse Liverpool CCG		December 2021

PGD adoption by the provider

Name	Job title and organisation	Signature	Date
Signatures to be determined locally, if relevant			

Training and competency of registered pharmacist

	Requirements of registered pharmacists working under the PGD
Qualifications and professional registration	Qualified pharmacist registered with the General Pharmaceutical Council (GPhC)
Initial training	Competent to work under Patient Group Directions, including satisfactory completion of training to administer/supply in accordance with this Patient Group Direction.
Competency assessment	CPPE Declaration of Competence Documents (DoCs)
Ongoing training and competency	<p>Commitment to continuing updating and re-validation according to the accreditation requirements of the commissioning organization.</p> <p>Commitment to keep up-to-date with clinical developments in this area or changes to the recommendations for the medicine listed, as part of their Continual Professional Development.</p>

Clinical condition

Clinical condition or situation to which this PGD applies	Treatment of oral candidiasis (thrush) in infants.
Inclusion criteria	<p>Babies over 1 month and under 2 years of age presented by parent/carer in the pharmacy with signs of oral thrush e.g. white plaques which do not move (not to be confused with milk curds in the mouth) under the minor ailments service.</p> <p>Carer agrees to treatment under this PGD.</p>
Exclusion criteria	<ul style="list-style-type: none"> Children over of 2 years and over – supply should be made as part of Care at the Chemist, rather than Pharmacy First Infants with known hypersensitivity/allergy to nystatin or any other excipient in the product. If child is unwell or on immunosuppressant therapy. Children with diabetes, haematinic deficiencies or poor dental hygiene. If this episode is a recurrence within the last 8 weeks. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> Refer to Summary of Product Characteristics http://www.medicines.org.uk/emc/
Arrangements for referral for medical advice	<ul style="list-style-type: none"> Supply the carer with a referral note to hand to the GP indicating the reasons for the referral.
Action to be taken if patient excluded	<p>If on age ground and two years or older, supply under Care at the Chemist protocols</p> <ul style="list-style-type: none"> Refer to GP practice. Clearly record the decision on the patient's consultation proforma including any advice given and action taken
Action to be taken if carer declines treatment	<p>Record the decision on the patient's consultation proforma including any advice given and action taken. Refer to GP as appropriate.</p>

Details of the medicine

Name, form and strength of medicine	Nystatin oral suspension 100,000 units in 1ml
Legal category	POM
Indicate any off-label use (if relevant)	
Route/method of administration	Oral
Dose and frequency	Give 100,000 units (1ml) of suspension into the mouth four times a day usually for 7 days and continued for 48 hours after lesions have resolved. Dose to be given after feeds. (Dose taken from BNF and BNFc).
Quantity to be administered and/or supplied	Supply 1 x 30ml The generic formulation should be supplied. A second bottle can be supplied if the episode continues beyond 7 days
Maximum or minimum treatment period	Maximum treatment period 10 days.
Adverse effects	<ul style="list-style-type: none"> • Local irritation and sensitization. • Nausea has occasionally been reported. • Large doses can cause diarrhoea, gastrointestinal distress, nausea and vomiting. • Rash including urticarial rash. • Steven-Johnson Syndrome has been reported very rarely. • Hypersensitivity and angioedema, including facial oedema have been reported. <p>Refer to SPC or current BNF/BNFc for full details.</p>
Records to be kept	<p>The following will be recorded in the patient's consultation proforma:</p> <ul style="list-style-type: none"> • Advice given to parent or carer • Baby's name, address, date of birth and GP (if registered) • Date and time of supply • The batch number and expiry date • Name of person supplying the medicine

Patient information

Verbal/written advice to be given to patient / carer	<p>Discuss side effects and administration with the parent/carer and provide a manufacturer's patient information leaflet.</p> <p>Advise the parent/carer how to use the product.</p> <p>The longer the suspension is kept in contact with the affected area in the mouth before swallowing the greater the effect.</p> <p>Advise parent/carer to discard any unused suspension after completing the treatment.</p> <p>The suspension should be given after feeds.</p> <p>Refer to the Medicines for Children Leaflet: https://www.medicinesforchildren.org.uk/nystatin-candida-infection</p>
Follow-up advice to be given to patient or carer	<p>Contact GP if symptoms persist beyond 10 days, or recurs</p>

Appendices

Appendix A Key references

1. Clinical Knowledge Summaries Guideline. Candida oral. (Accessed October 2021)
2. Nystan SPC Summary of Product Characteristics (Accessed October 2021)
3. Nystatin SPC Supply of Product Characteristics (Accessed October 2021)
4. BNFc (Accessed October 2021)

Appendix B Health professionals' agreement to practise

I have read and understood the Patient Group Direction and agree to supply this medicine only in accordance with this PGD.

Name of pharmacist	Signature	Senior representative authorising pharmacist	Date